Cambridge Antibody Technology Partners With Chugai to Develop Novel Human Monoclonal Antibodies
Monday September 30, 3:08 am ET MELBOURN, England, Sept. 30 /PRNewswire-FirstCall/ -- Cambridge Antibody Technology (Nasdaq: CATG - News; LSE: CAT - News) today announces an agreement with Chugai Pharmaceutical Co., Ltd. (TSE 4519), of Japan to license CAT's proprietary antibody phage display libraries for the discovery, development and commercialization of human monoclonal antibodies.
Under the terms of the agreement, CAT will receive license fees from Chugai to utilize the antibody libraries for reagent generation and target validation in support of drug discovery programs at Chugai. In addition, Chugai will receive exclusive therapeutic antibody product options and CAT will receive fees, clinical milestones and royalty payments on product sales.
Peter Chambre, Chief Executive Officer of CAT, commented, "We are delighted to license CAT's human antibody libraries to Chugai, one of the leading Japanese pharmaceutical companies. We look forward to working closely with Chugai to accelerate their programs to validate human disease-associated targets and discover therapeutic human antibody drugs. This new collaboration with Chugai is important in that it further expands the number of major companies utilizing CAT's technology and capability and allows CAT to participate in the value generated by our partner's development and commercialization of human antibody drugs."
Dr. Tatsumi Yamazaki, Vice President of Research of Chugai, added, "Chugai has established a unique competitive edge in the development of therapeutic antibodies. We have high expectation that this partnership with CAT will further accelerate Chugai's research and development processes including the screening and validation of antibodies." ... |
